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Abstract: B a c k g r o u n d: Despite progress in the invasive treatment of ischemic heart disease, the 
ability to limit ischemia-reperfusion (I/R) injury remains largely unrealized. Ischemic pre-conditioning 
(IPC) and post-conditioning (POC) induce the protective mechanisms of resistance against I/R injury. 
Stimulation of opioid receptors mimic the protective eff ect of IPC or POC in an animal models. We tested 
the hypothesis, that IPC and POC provide cardioprotection in opioid-dependent mechanism in human 
myocardium. 
M e t h o d s: Human atrial trabeculae were subjected to I/R injury. To achieve IPC, single hypoxia pe-
riod preceded the applied lethal hypoxia, to achieve POC triple hypoxia periods followed lethal hypoxia. 
Naloxone was used at the onset of lethal hypoxia in IPC protocol, and at the time of re-oxygenation in 
POC protocol. Contractive function of the myocardium was assessed as maximal force of contraction 
(Amax), rate of rise of force of contraction (+dV/dT) and diastolic parameter — rate of decay of force of 
contraction (–dV/dT).
R e s u l t s: Co-application of naloxone with IPC or POC resulted in decrease of Amax, +dV/dT and 
–dV/dT during re-oxygenation period as compared to IPC or POC only.
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C o n c l u s i o n s: Naloxone abrogates benefi cial eff ect of IPC and POC. IPC and POC in humans provide 
cardioprotection in opioid receptor system dependent mechanism.
Key words: ischemia, naloxone, post-conditioning, pre-conditioning, reperfusion.
Introduction
Ischemic heart disease remains the main cause of morbidity and mortality in 
developed countries. Th e restoration of coronary fl ow is mandatory to reduce 
ischemic myocardial damage and may save to some degree contractile function to the 
ischemic heart muscle. However, reperfusion has the potential to exacerbate lethal 
tissue injury in the mechanism known as ischemia/reperfusion (I/R) injury which in 
clinical settings manifests as the decrease of potential benefi ts of reperfusion [1,  2]. 
Sequences of brief ischemia periods applied before (preconditioning — IPC) or aft er 
(post-conditioning — POC) coronary occlusion are well documented to trigger 
protective mechanisms to the heart muscle against I/R injury [3–7]. Th e mechanisms 
underlying IPC or POC are still not clarifi ed, but experimental evidence with an 
animal models, suggested that opioids may be part of the endogenous cardioprotective 
response to I/R injury [8, 9].
Th e current study was the fi rst time taken to delineate the eff ect of non-selective 
opioid receptor antagonist, naloxone, on the protective eff ect evoked with IPC or 
POC in the human ischemic myocardium.
Materials and methods
Th e Local Bioethics Committee approval for the use of human tissue was obtained 
and individual patient consent was waived. All experiments were performed according 
to the principles stated in the Declaration of Helsinki.
Th e experiments were performed on muscular trabeculae obtained from the right 
heart atrial appendages of 58 consecutive patients (35 males/23 females) subjected 
to coronary artery bypass surgery. Patients diagnosed with signifi cant valvular heart 
disease or with severe heart failure therapy were excluded from the study. 
Th e fragments of the human right heart atria were transported from the cardiac 
surgery room to the laboratory in an ice-cold Krebs-Henseleit solution ([M]: NaCl 118.0, 
KCl 4.70, CaCl2 1.52, MgSO4 1.64, NaHCO3 24.88, KH2PO4 1.18, glucose 11.0, and 
sodium pyruvate 2.0; pH 7.4). Two muscular trabeculae, each less than 1 mm in diameter, 
were dissected from the right heart atria and incubated in 2 separate organ baths (Schuler 
Organbath, Hugo Sachs Elektronik, March-Hugstetten, Germany [HSE]) both fi lled with 
Krebs-Henseleit solution warmed up to 37°C. 
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Table 1. Th e patients’ demographic information and the preoperative pharmacotherapy.
1 Men/Women 35/23
2 Age (years) 62.8 ± 5.7
3 Ejection fraction (mean ± SD) 52.3 ± 2.39%
4a Diabetes 12
4b Diabetes with insulin treatment  7
5 Drugs  
5a Beta-blockers n = 43 (75%)
5b Calcium channel blockers n = 10 (18%)
5c Angiotensin II converting enzyme inhibitors n = 30 (52%)
5d Angiotensin II receptor blockers n = 2  (3%)
5e Statins n = 40 (69%)
Two trabeculae from each patient were always studied simultaneously and 
exposed to hypoxia protocol including: 60 min of hypoxia (incubation in Krebs-
-Henseleit buff er deprivated of glucose and pyruvate and saturated with 95% argon 
and 5% carbon dioxide) with subsequent 60 min of re-oxygenation (incubation in 
Krebs-Henseleit buff er saturated with the 95% oxygen and 5% carbon dioxide). Th e 
buff er was replaced every 15’, except the time of hypoxia.
Protocols
Th e study protocols are presented in Fig. 1. To achieve IPC, the single brief hypoxia 
period preceded the applied 60’ lethal hypoxia, whereas POC protocol consisted of 
3 times repeated sequence of 1-min re-oxygenation with subsequent 1-min hypoxia 
applied at the beginning of 60 min re-oxygenation. Th e number of the ischemic 
cycles was based on previously published data [10, 11]. To determine the eff ects of 
opioid receptor blockade on IPC or POC, non-selective opioid receptor antagonist, 
naloxone (10–5M) was administered at the onset of lethal hypoxia in the IPC protocol, 
and at the time of re-oxygenation in the POC protocol. Th e second trabecula was 
subjected IPC or POC protocol only. Every trabecula was stretched to 90% of its 
optimal tension strength, according to the Frank-Starling relationship and all trabeculae 
were driven throughout experiments with 1 Hz 50 ms square stimuli using platinum 
fi eld electrodes and a  stimulator (Type 215, HSE). Th e systolic function of every 
trabecula was recorded with the use of F30 isometric force transducer (Type 372, HSE). 
Th e signal was enhanced with a  bridge amplifi er (Type 336, HSE) and recorded by 
a  PowerLab/4SP system and analyzed off -line using Chart soft ware (AD Instruments, 
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Chalgrove, Oxfordshire, UK). Each experimental protocol was completed with 10 μM 
of norepinephrine (NE) application to assess the viability of trabeculae. Th e contractive 
force of the myocardium assessed as the maximal force of contraction (Amax[mV]), 
the rate of rise of the force of a  contraction (+dV/dT) and diastolic parameter — 
the rate of decay of the force of a contraction (–dV/dT) were obtained in 5th, 10th, 15th, 
30th, 45th and 60th min of re-oxygenation and aft er the NE application. 
Fig. 1. Protocols for the experimental groups. All protocols were preceded by a  stabilization period of 
45 to 60 min. Th is was followed by 60 min of simulated ischemia (superfusion with hypoxic, substrate 
free Krebs-Henseleit solution and pacing at 1 Hz) and 60 min of superfusion with reoxygenated 
Krebs-Henseleit solution.
Data analysis
Th e results were presented as the percent of values obtained before experimental 
protocol application. All continuous data were normally distributed and were 
presented as a  mean ± standard error of the mean (SEM). Two-way analysis of 
variance (ANOVA) followed by Holm-Sidack’s test was used to compare the results of 
values from 5th to 60th min of re-oxygenation. A p value less than 0.05 was considered 
statistically signifi cant. Statistical analysis was performed using SigmaPlot soft ware 
(ver. 10.0.1.2. Systat Soft ware Inc. San Jose, CA, USA).
Results
Th ere were no signifi cant diff erences in age, sex and pharmacotherapy between the 
patients from which the trabeculae were taken and were subjected to IPC, POC or 
naloxone protocols. Th e results are presented in Fig. 2.
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Fig. 2. The effect of ischemic pre-conditioning (IPC), post-conditioning (POC) with/without 
naloxone  (NX) on function of human myocardium during the re-oxygenation period. Figures present 
analysis of the systolic parameters as maximal force of contraction (Amax), the rate of rise of the 
force of a contraction (+dV/dT) and diastolic parameter — the rate of decay of the force of a contraction 
(–dV/dT). Th e results analysed by two-way ANOVA during the re-oxygenation period.
Th e co-application of naloxone 10–5M with IPC resulted in the decrease of Amax, 
+dV/dT and –dV/dT during re-oxygenation period as compared to IPC protocol only. 
Th e results were as follows: naloxone + IPC vs. IPC for Amax, +dV/dT, –dV/dT: 
67.99 ± 3.6% vs. 77.54 ± 6.3%*; 27.63 ± 1.9% vs. 34.70 ± 3.4%*; 34.15 ± 1.8% vs. 
41.25 ± 3.1%*, respectively, *p <0.05. 
Th e co-application of naloxone 10–5M with POC resulted in the decrease of Amax. 
Th e results were as follows: naloxone + POC vs. POC for Amax, +dV/dT, –dV/dT: 
65.73 ± 1.5% vs. 73.90 ± 2.6%*; 39.80 ± 2.1% vs. 43.28 ± 3.6%; 45.05 ± 1.9% vs. 
48.97 ± 3.3%, respectively, *p <0.05.
Discussion
Early restoration of coronary artery blood fl ow following an acute occlusion may limit 
ischemic heart muscle injury. However reperfusion may itself induce cardiomyocyte 
death. Th is phenomenon is known as the ischemia/reperfusion (I/R) injury. Th e 
concept of ischemic conditioning include the endogenous cardioprotective eff ect 
obtained by applying brief non-lethal episodes of ischemia and reperfusion to the 
heart [10]. Benefi cial eff ects of cardioprotective strategies: pre- and post-conditioning 
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have been described in many experimental studies in an animal models of 
myocardial infarction  [11–13]. Th e number and duration of each phase of hypoxia 
and reoxygenation is essential but effi  ciency of the protocols is typically variable. 
Th e most eff ective protocol for human myocardium described in the experimental 
studies consisted of a 5-minute period of hypoxia and 5 minute reoxygenation period 
preceding the lethal hypoxia [14], what was presented also in our previous studies [15].
In the current study we used the isolated fragments of human atrial tissue, 
harvested from patients subjected to cardiac surgery. Th is model of human heart 
ischemia provides a  possibility to determine the influence of cardioprotective 
strategies taking into the consideration the all factors potentially aff ecting the results 
of the study, like comorbidities or pharmacotherapy. Th is method allowed us to assess 
contractile force of myocardium, although ventricular muscle would be preferable. 
This method allowed us to determine whether the beneficial effect of ischemic 
preconditioning or post-conditioning is mediated via opioid receptor stimulation in 
the human heart muscle. Th e current results showed that non-selective blockade of 
opioid receptors completely abolished the protective eff ect of IPC and POC, what 
has been demonstrated by decreased systolic and diastolic parameters aft er naloxone 
administration, comparing with IPC or POC protocols only. Our fi nding supports the 
statement that opioid receptor stimulation protects the heart muscle against ischemia/
reperfusion injury by mimicking pre- or post-conditioning.
Previous studies on the animal model of heart ischemia have shown that opioid 
receptors are present in cardiomyocytes. In adult rat heart muscle, δ-, κ-opioid 
receptors are considered, but μ-opioid receptors are absent [16]. Thus, based on 
the studies with animal models, the δ- and κ-opioid receptors are implicated in 
cardioprotection including anti-infarct and anti-arrhythmic eff ect, although there 
are few researches presenting results controvert to the previous reports indicating 
detrimental infl uence of κ-opioid receptor activation [17]. Unexpectedly, benefi cial 
effect of selective μ-opioid receptor agonist — remifentanil was shown in adult 
rats [18]. Whether this eff ect is involved in cross-talk with other opioid receptors or 
may infl uence extracardiac μ-opioid receptors, remains to be determined. Whereas, 
in humans, the presence of all subtypes of opioid receptors in the cardiac tissue was 
proven with PET imaging [19]. 
Few clinical trials have provided evidence for beneficial effect of opioids in 
patients subjected to coronary artery bypass graft ing (CABG) or coronary angioplasty. 
For example remifentanil has been shown to reduce cardiac injury markers in 
perioperative CABG period [20, 21]. Despite promising results in experimental 
studies, the main limitation of the IPC is a  lack of possibility of application of 
brief ischemia/reperfusion episodes at the beginning of ischemia or before clinical 
symptoms. Noda et al. presented protective eff ect of a  fi rst pre-infarction angina in 
patients before developing acute heart infarction, compared with patients who had 
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a heart infarction as the fi rst manifestation of coronary artery disease, what indicates 
the existence of the IPC eff ect in humans [22]. Moreover, post-conditioning may 
reduce the occurrence of malignant ventricular arrhythmias in patients with STEMI 
treated with primary coronary angioplasty [23]. Clinical applicability of IPC is limited 
to cardiosurgical and transplantological procedures. Th e results of recently published 
randomized trial ERICCA showed that remote ischemic preconditioning did not 
improve clinical outcomes in patients undergoing elective on-pump CABG with or 
without valve surgery [24]. Post-conditioning eff ect in clinical setting was achieved 
aft er percutaneous revascularization by interrupting myocardial reperfusion with 
six cycles of infl ation and defl ation of coronary angioplasty balloon. Th is protocol 
has been reported to reduce myocardial infarct size at 6 months and preserve the 
left ventricular ejection fraction at 1 year [25], but large multicenter studies are 
required to determine the eff ect of cardioprotective strategies on clinical outcomes. 
The encouraging results of animal model of cardioprotection are not adequately 
representative for clinical settings. Lack of strong outcomes dampens the enthusiasm 
of researchers about clinical application of preconditioning. Hovewer, opioids may 
mimic the eff ect of pre- or post-conditioning involving a similar intracellular pathway, 
or acting in not fully known mechanism [26].
Limitations
The results must be interpreted within the limitations of the methodology. 
Construction of our experiment assumes a  control group derived from the same 
patient and the same factors potentially aff ecting the test. We must note, however 
that simulated ischemic model diff ers from in vivo condition. In our experiment 
we utilized the buff er, so there we no elements transporting or binding opioids, like 
peptides. However, the pathophysiological and functional changes that take place 
in our model of I/R injury are comparable to the change that takes place in in vivo 
conditions.
Conclusions
Naloxone completely abrogates benefi cial eff ect of both cardioprotective strategies — 
ischemic pre-conditioning and post-conditioning. Th ese data suggest that ischemic 
pre-conditioning and post-conditioning in humans provide cardioprotection in opioid 
receptor system dependent mechanism.
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List of abbreviations
Amax — maximal force of the contraction
ANOVA — two-way analysis of variance 
CABG — coronary artery by-pass graft ing
I/R injury — ischemia/reperfusion injury
IPC — ischemic preconditioning
NE — norepinephrine
NX — naloxone
OR — opioid receptor
POC — ischemic postconditioning
SEM — standard error of the mean
STEMI — ST-elevation myocardial infarction
+dV/dT — the rate of rise of the force of a contraction
–dV/dT — the rate of decay of the force of a contraction
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